Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Isotype of this product is: (VH-CH2-CH3)2
Envafolimab (KN035) is the world's first new fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc. Compared with the PD-1/PD-L1 antibodies currently on the market and under development, it has a distinct advantage . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and fast tumor penetration, which can improve the compliance of tumor patients and improve the quality of life of patients, which is in line with the future trend of long-term management of tumors as chronic diseases.
仅用于科研。不用于诊断过程。未经明确授权不得转售。